SCIENCE 37 HOLDINGS INC (SNCE) Stock Price, Quote, News and Overview
NASDAQ:SNCE - Nasdaq - US8086442071 - Common Stock - Currency: USD
SNCE Quote, Performance and Key Statistics
5.75
+0.02 (+0.35%)
The current stock price of SNCE is 5.75 USD. In the past month the price increased by 1.23%. In the past year, price decreased by -19.47%.
SNCE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 24.36 | 203.70B | ||
| DHR | DANAHER CORP | 28.07 | 151.18B | ||
| A | AGILENT TECHNOLOGIES INC | 25.59 | 38.62B | ||
| IQV | IQVIA HOLDINGS INC | 17.15 | 33.64B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 31.26 | 26.91B | ||
| WAT | WATERS CORP | 31.58 | 22.26B | ||
| ICLR | ICON PLC | 14.39 | 16.63B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 31.25 | 15.27B | ||
| ILMN | ILLUMINA INC | 38.45 | 14.94B | ||
| RVTY | REVVITY INC | 23.23 | 13.85B | ||
| AVTR | AVANTOR INC | 17.3 | 11.78B | ||
| TEM | TEMPUS AI INC | N/A | 10.72B |
Related stock screener links
About SNCE
Company Profile
Science 37 Holdings Inc is a US-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Research Triangle Park, North Carolina and currently employs 460 full-time employees. The company went IPO on 2020-11-20. Science 37 Holdings, Inc. is engaged in patient-centric clinical trials and in supporting novel approaches to decentralized clinical trial designs. Through its patient-centric approach, it reduces the impact of the geographic barriers associated with conventional physical clinical trial sites, enabling recruitment of virtually any patient. Its offerings lie in its configurable unified technology platform combined with its centralized patient recruitment capabilities and specialized network of patient communities. Its unified technology platform is purpose-built for patient-centric clinical trial execution and is designed to provide an end-to-end, single stop solution. The company also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, and remote coordinators designed for the purpose of orchestrating patient-centric clinical trials. The company uses diversified, multi-channel programs to identify patients who fit the profile for each of its projects.
Company Info
SCIENCE 37 HOLDINGS INC
800 Park Offices Drive, Suite 3606
RESEARCH TRIANGLE PARK NORTH CAROLINA US
CEO: Andrew McDonald
Employees: 460
Company Website: https://lifesciacquisition.com
Phone: 19843773737
SCIENCE 37 HOLDINGS INC / SNCE FAQ
What is the stock price of SCIENCE 37 HOLDINGS INC today?
The current stock price of SNCE is 5.75 USD. The price increased by 0.35% in the last trading session.
What is the ticker symbol for SCIENCE 37 HOLDINGS INC stock?
The exchange symbol of SCIENCE 37 HOLDINGS INC is SNCE and it is listed on the Nasdaq exchange.
On which exchange is SNCE stock listed?
SNCE stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SCIENCE 37 HOLDINGS INC stock?
10 analysts have analysed SNCE and the average price target is 14.11 USD. This implies a price increase of 145.39% is expected in the next year compared to the current price of 5.75. Check the SCIENCE 37 HOLDINGS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SCIENCE 37 HOLDINGS INC worth?
SCIENCE 37 HOLDINGS INC (SNCE) has a market capitalization of 34.67M USD. This makes SNCE a Nano Cap stock.
How many employees does SCIENCE 37 HOLDINGS INC have?
SCIENCE 37 HOLDINGS INC (SNCE) currently has 460 employees.
What are the support and resistance levels for SCIENCE 37 HOLDINGS INC (SNCE) stock?
SCIENCE 37 HOLDINGS INC (SNCE) has a support level at 5.73 and a resistance level at 5.76. Check the full technical report for a detailed analysis of SNCE support and resistance levels.
Is SCIENCE 37 HOLDINGS INC (SNCE) expected to grow?
The Revenue of SCIENCE 37 HOLDINGS INC (SNCE) is expected to decline by -14.69% in the next year. Check the estimates tab for more information on the SNCE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SCIENCE 37 HOLDINGS INC (SNCE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SNCE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SNCE, evaluating the profitability, health, valuation and growth aspects
- SCIENCE 37 HOLDINGS INC (SNCE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SCIENCE 37 HOLDINGS INC (SNCE) Sales and EPS estimates to see what analysts future expectations are.
- SCIENCE 37 HOLDINGS INC (SNCE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SCIENCE 37 HOLDINGS INC (SNCE) Insider and Institutional Ownership to learn about the owners and their transactions.
- SCIENCE 37 HOLDINGS INC (SNCE) Stock Chart to make your own analysis
- SCIENCE 37 HOLDINGS INC (SNCE) Latest news and press-releases to stay up to date.
Does SCIENCE 37 HOLDINGS INC (SNCE) stock pay dividends?
SNCE does not pay a dividend.
When does SCIENCE 37 HOLDINGS INC (SNCE) report earnings?
SCIENCE 37 HOLDINGS INC (SNCE) will report earnings on 2024-05-13, before the market open.
What is the Price/Earnings (PE) ratio of SCIENCE 37 HOLDINGS INC (SNCE)?
SCIENCE 37 HOLDINGS INC (SNCE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-7.26).
SNCE Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to SNCE. When comparing the yearly performance of all stocks, SNCE is a bad performer in the overall market: 70.82% of all stocks are doing better.
SNCE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SNCE. The financial health of SNCE is average, but there are quite some concerns on its profitability.
SNCE Financial Highlights
Over the last trailing twelve months SNCE reported a non-GAAP Earnings per Share(EPS) of -7.26. The EPS decreased by -881.08% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -164.66% | ||
| ROE | -241.1% | ||
| Debt/Equity | 0 |
SNCE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 76% to SNCE. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of -72.66% and a revenue growth -14.69% for SNCE